BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7255768)

  • 1. Arginine vasopressin and a vasopressin antagonist peptide: opposite effects on extinction of active avoidance in rats.
    Koob GF; Le Moal M; Gaffori O; Manning M; Sawyer WH; Rivier J; Bloom FE
    Regul Pept; 1981 Jun; 2(3):153-63. PubMed ID: 7255768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central injections of arginine vasopressin prolong extinction of active avoidance.
    Koob GF; Dantzer R; Bluthé RM; Lebrun C; Bloom FE; Le Moal M
    Peptides; 1986; 7(2):213-8. PubMed ID: 3737445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressin pressor antagonist injected centrally reverses behavioral effects of peripheral injection of vasopressin, but only at doses that reverse increase in blood pressure.
    Lebrun C; Le Moal M; Koob GF; Bloom FE
    Regul Pept; 1985 Jun; 11(2):173-81. PubMed ID: 4035008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonism of effects of vasopressin (AVP) on inhibitory avoidance by a vasopressin antagonist peptide [dPtyr(Me)AVP].
    LeBrun CJ; Rigter H; Martinez JL; Koob GF; Le Moal M; Bloom FE
    Life Sci; 1984 Oct; 35(14):1505-12. PubMed ID: 6482669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of vasopressin and analogue [d(CH2)1(5), Tyr (Me)2, Val4, delta 3Pro7)] AVP on learning and memory in rats chronically treated with ethanol.
    Car H; Borawska MH; Wiśniewski K
    J Physiol Pharmacol; 1994 Mar; 45(1):163-71. PubMed ID: 8043905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular effects of arginine vasopressin during fluid deprivation in the rat.
    Aisenbrey GA; Handelman WA; Arnold P; Manning M; Schrier RW
    J Clin Invest; 1981 Apr; 67(4):961-8. PubMed ID: 7204578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
    Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
    J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
    Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
    J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertonic saline mimics the effects of vasopressin on inhibitory avoidance in the rat.
    Lebrun C; Le Moal M; Dantzer R; Bloom FE; Koob GF
    Behav Neural Biol; 1987 Mar; 47(2):130-7. PubMed ID: 3579833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor?
    de Wied D; Elands J; Kovács G
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1494-8. PubMed ID: 1847526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of vasopressin analog [d(CH2)1(5),Tyr(Me)2]AVP on learning and memory in rats chronically treated with ethanol.
    Car H; Borawska MH; Wiśniewski K
    Pol J Pharmacol; 1993; 45(5-6):503-12. PubMed ID: 8012473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of potent antagonists of the vasopressor response to arginine-vasopressin.
    Bankowski K; Manning M; Haldar J; Sawyer WH
    J Med Chem; 1978 Sep; 21(9):850-3. PubMed ID: 722751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pinealectomy blocks modulation of active avoidance by central vasopressin application in rats.
    Appenrodt E; Schwarzberg H
    Peptides; 2003 Jan; 24(1):129-36. PubMed ID: 12576094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The slowing of the extinction of a conditioned reaction and the antiamnesic action of arginine vasopressin and des-glycine-(8-arginine) vasopressin].
    Dubrovina NI; Papsuevich OS; Chipens GI
    Farmakol Toksikol; 1991; 54(5):5-7. PubMed ID: 1800150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged inhibition of pressor response to vasopressin by a potent specific antagonist, [1-(beta-mercapto-beta, beta-cyclopentamethylenepropionic acid) 2-(O-methyl)tyrosine]arginine-vasopressin.
    Pang CC; Leighton KM
    Can J Physiol Pharmacol; 1981 Sep; 59(9):1008-12. PubMed ID: 6895346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osmotic stress mimics effects of vasopressin on learned behaviour.
    Koob GF; Dantzer R; Rodriguez F; Bloom FE; Le Moal M
    Nature; 1985 Jun 27-Jul 3; 315(6022):750-2. PubMed ID: 4010780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of peripherally injected vasopressin and des-glycinamide vasopressin on the extinction of a spatial learning task in rats.
    Packard MG; Ettenberg A
    Regul Pept; 1985 May; 11(1):51-63. PubMed ID: 4011956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic intracerebral infusions of vasopressin and vasopressin antagonist modulate behavioral effects of interleukin-1 in rat.
    Bluthé RM; Dantzer R
    Brain Res Bull; 1992 Dec; 29(6):897-900. PubMed ID: 1473021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin antagonists block peripheral as well as central vasopressin receptors.
    De Wied D; Gaffori O; Van Ree JM; De Jong W
    Pharmacol Biochem Behav; 1984 Sep; 21(3):393-400. PubMed ID: 6093152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of the nature of the interaction between vasopressin and corticotropin-releasing factor on adrenocorticotropin release in the rat.
    Rivier C; Rivier J; Mormede P; Vale W
    Endocrinology; 1984 Sep; 115(3):882-6. PubMed ID: 6086290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.